Tag: CYP2D6

By Posted on Posted in Adverse Drug Reaction [ADR], Allelic Variant, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Serious Adverse Drug Reaction (sADR), Thasso Post, Theragenomic Medicine, Theragenomics of Individualized Drug Safety Tagged with , , , , , , ,

March 30, 2025 – A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the UK medicines regulator are associated with medications where side effect risk is partly dependent …

Can testing for three genes prevent 75% of avoidable side effects for certain medications? Read more »

By Posted on Posted in Genetic Susceptibility, New Safety Information, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , ,

July 6. 2015 – The American Food and Drug Administration (FDA) is once more investigating the safety of using codeine-containing medicines to treat coughs and colds in children under 18 years because of the potential for serious side effects, including …

Codeine cough-and-cold medicines in children: A never ending story – FDA evaluating potential risk of serious side effects Read more »

By Posted on Posted in Thasso Post Tagged with , , , , , , , ,

12. Oktober 2012 – Kürzlich berichtete die US-amerikanische Zulassungsbehörde FDA über drei Todesfälle und einen Fall einer lebensbedrohlichen Atemdepression nach Einnahme von Codein bei Kindern im Alter von 2-5 Jahren. In allen vier Fällen wurde Codein unter Beachtung der empfohlenen …

Codein und Todesfälle bei Kindern: Genetischer Polymorphismus in CYP2D6 Read more »